With semaglutide’s patent expiring in 2026, Indian drugmakers are racing to launch generics of Ozempic and Wegovy, aiming for a multibillion-dollar opportunity
India’s $73 million weight-loss drug market has grown fivefold in five years, driven by rising obesity and diabetes rates. Generics could make treatments far more accessible
Pharma giants are pushing back. Novo Nordisk is suing Indian firms, and others like Eli Lilly are seeking follow-on patents to delay generic competition
Rapid scaling by Indian manufacturers may bypass critical safety protocols. Recent drug contamination scandals highlight the dangers of weak oversight
In India, over-the-counter access and self-dosing are widespread. Without medical supervision, these potent drugs could cause serious harm to users
As India enters the generic weight-loss drug era, regulatory vigilance is essential to protect public health and prevent a secondary health crisis